Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients

IRVING, TX--(Marketwired - January 29, 2015) - Reata announces enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia. 

Read More: Reata Enrolls First Patient in the MOXIe Study...




News & Press Archives

Privacy Policy      Service Terms      Contact      Charity Navigator